Airtech Seeks Medicare Approval -- For Medicare Reimbursement to Medicare Recipients for Airtech's Portable Photocatalytic Air Sterilizing Unit.

DALLAS--(BUSINESS WIRE)--Oct. 12, 1999--

Airtech International Group, Inc., (OTCBB:AIRG) Announced today, the filing of an application with the Medicare Benefits Administration for approval of the company's portable air sterilization unit designed specifically for the Medicare recipient.

The model S-950 includes technology believed to be a "first" in successfully miniaturizing components into an efficient portable unitf patients suffering from asthma, emphysema, COPC, chronic bronchitis and pneumonia. The "user friendly" unit purifies the air of harmful particulate and gas molecules. Particulate have been singled out as one of the primary "triggers" to asthmatic attacks and other upper respiratory diseases which hospitalize tens of thousands of patients every year and reportedly cost Medicare billions of dollars in claims. It is currently estimated that there are currently over 40 million Medicare recipients -- a number that is expected to double by the year 2008.

Airtech's Model S-950 is a highly sophisticated piece of technology incorporating a state-of-the-art filtration and sterilization process. The new unit features a dual gas absorption layer, hospital grade HEPA filter, high output germicidal ultraviolet lamp combined with Photocatalytic Oxidation (PCO). Additional features include an Infrared Motion Detector that senses the presence of the patient and other moving objects in the area and automatically increases air purifier/sterilization performance -- a Toxic Chemical Sensor to Monitor Air Quality and a Service Monitoring system that indicates when filters need to be changed. No other portable technology exists in the marketplace that incorporates all these features and bottom-line performance. With a breakthrough in miniaturization of components, the Model S-950 measures just 21.5 inches in width, 18 inches in height, 8 inches in depth. The unit weighs approximately 23 pounds.

Airtech CEO, C.J. Comu stated, "Airtech's testing and research indicates that the use of the S-950 air sterilizer by Medicare recipients who suffer from chronic upper respiratory disease such as asthma, chronic bronchitis, and emphysema will save the Medicare xposure to harmful volatile organic compounds particulate, as well as airborne fungi, bacteria and viruses that cause patients with chronic illness to become acutely ill."

Distribution of the S-950 will be through a national network of Durable Medical Equipment Dealers (DME's). There are currently over 10,000 DME's in the United States. The S-950 retail price point for the product is $795.00. According to DME marketing organization, BESS International's President, Chris Uhland, "We have talked to other national DME's and upon approval by Medicare, we have preliminary commitments to sell up to 20,000 units per month."

Medical opinions vary, but the best estimate is that through the use of this device with certain classes of chronically ill elderly patients, it is estimated that the Federal Health Programs savings could be in excess of $100,000,000 dollars. Acclly for smoking related diseases of Medicare recipients alone.

Airtech's Medical Director R. John Harris, stated "The technology is capable of destroying virtually erly, and patients with baseline conditions of involves the action of low-energy, ultra violet light, focused on a catalyst in the presence of water vapor, which generates hydroxyl radicals that destroy microbes in thl oxidize volatile organic compounds (VOCs) adsorbed on the catalytic surface. This process is referred to as heterogeneous photocatalysis or, more specifically, photocatalytic oxidation.

The new product will be marketed under the trademark Airsopure PCO(R). Airsopure Incorporated is the wholly owned marketing subsidiary of Airtech, which supplies solutions to the commercial community with a diverse line of air purification equipment. The addition of a medical unit featuring PCO should further position both Airtech and Airsopure as the leaders in air purification for the twenty-first century.

The Airsopure PCO(R) captures and destroys 98% of airborne bacteria, including mycobacterium tuberculosis fungi and viruses, and 100% of mold spores. Airsopure(R) Photocatalytic Oxidation is able to also adsorb and destroy acetone, benzene, carbon monoxide, methyl ethyl ketone (MEK), styrene, toluene and deadly carbon monoxide (CO).

Airtech first achieved market recognition with its air purification technology by providing a simple solution that allows smokers and non-smokers to co-exist in restaurants and bars. Its corporate customers include: Denny's, Bennigan's, Del Frisco's Double Eagle Steakhouses, Sullivan's, Host Marriott Services and hundreds of other food and beverage related companies. Today, the Company's primary focus is on schools, hotels, office complexes, casinos and healthcare. Airtech International Group (www.airtechgroup.com), (www.airsopure.com) is a publicly traded company under the symbol (OTCBB:AIRG). Investors may obtain more information by contacting the Company at 972/960-9400 or Fax: [phone], or by contacting the Company's IR firm, Demonte & Associates at 212/473-3700.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements contained in this document which are not historical fact are forward-looking statements based upon management's current expectations that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by forward looking statements. These risks are described in the Company's Form 10-KSB for the fiscal year ending May 31, 1999, filed with the Securities Exchange Commission.